This recent transaction increases Deborah Andrews’ holding in the company by 19.1% to a total of $22.2K.
Based on BioTime’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $2.55 million and GAAP net loss of $4.22 million. In comparison, last year the company earned revenue of $381K and had a GAAP net loss of $11.65 million. Currently, BioTime has an average volume of 537.8K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioTime, Inc. is a clinical-stage biotechnology company, which deals with degenerative diseases. The company’s programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies.